Vancouver, British Columbia / June 8, 2020 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce that it’s US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), has initiated a collaboration with Dr. Brian Zeglis at the City University of New York to test APTI’s site specific conjugation technology in the rapidly growing field of radioimmunoconjugates (RICs). APTI will prepare RICs using its proprietary conjugation technology with antibodies targeting the HER2 receptor. The HER2 receptor is expressed on many malignancies with approved targeted therapeutics for breast and gastric cancer. Under the collaboration, RICs produced with APTI conjugation technology will be chemically characterized, imaged by PET and in vivo bio-distribution evaluated. The HER2 model utilized is well described and will generate valuable data about the behavior of APTI conjugates in vivo.
Bill Dickie, President and CEO of APTI commented “Radioimmunotherapy using alpha and beta emitting isotopes is an area of rapid development and investment. Major Pharma companies such as Bayer and Novartis have made multi-billion-dollar acquisitions in the field and a number of emerging companies have benefitted from significant venture funding.” We are excited to be working with Dr. Zeglis, a key opinion leader in the field, and with City University of New York’s state-of-the-art radiolabeling and PET imaging capability. This initiative will build on our previous successful proof of concept work with Noria Pharmaceuticals where we demonstrated the ability to homogeneously site specifically label antibodies with radioisotope chelators while maintaining antibody binding affinity.”
Dr. Brian Zeglis, Principal Investigator on the project and Assistant Professor, Department of Chemistry, Hunter College, City University of New York commented: “I am pleased to be working with APTI. Their unique approach to antibody conjugation has significant promise to address limitations in current immunoconjugate design including instability and resulting off-target toxicity.”
Paul Woodward, CEO of Advanced Proteome Therapeutics Corporation states “This collaboration is yet another step for APTI in proving the versatility and applicative breadth of its conjugation technologies, technologies that will enable the creation of safer and more efficacious cancer therapeutics for patients.”
ABOUT THE COMPANY:
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of superior antibody-drug conjugates through improved site-specific labeling, drug-antibody ratio control and enabling of combination payloads. The technology has compelling pre-clinical data demonstrating improved homogeneity and increased in-vivo potency relative to current state of the art linker technology. The Company believes that the technology will enable the development of safer and more potent antibody-drug conjugate therapeutics and is pursuing licensing and partnership opportunities to advance development and create shareholder value.
FOR FURTHER INFORMATION PLEASE CONTACT:
Advanced Proteome Therapeutics Corporation
President and CEO
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “intends”, “anticipates”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulators.
Readers are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that any forward-looking statement will materialize, and readers should not place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.